Introduction
Brand name: Linofast IV 300
Composition: Linezolid 300 mL infusion (equivalent to 600 mg linezolid in 300 mL bag, i.e., 2 mg/mL solution for intravenous infusion)
Linofast IV 300 is an intravenous oxazolidinone‑class antibiotic containing linezolid, used for the treatment of serious Gram‑positive bacterial infections, including those caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant enterococci (VRE). It inhibits bacterial protein synthesis at the initiation stage, thereby preventing the formation of functional 70S ribosomes. Linezolid is active against many resistant organisms and is primarily used in nosocomial pneumonia, complicated skin and soft‑tissue infections, and certain bloodstream infections.
Key indications
Hospital‑acquired and community‑acquired pneumonia caused by susceptible Gram‑positive pathogens.
Complicated skin and soft‑tissue infections (e.g., diabetic foot infections, post‑surgical infections).
Bloodstream infections and infections due to resistant organisms when conventional agents are inadequate or contraindicated.
Dosage and precautions
Standard adult dose is 600 mg linezolid (i.e., 1 bag of 300 mL / 600 mg) given by intravenous infusion every 12 hours,
